|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
EP4353819A3
(en)
*
|
2004-07-22 |
2024-07-17 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
|
GB0601511D0
(en)
*
|
2006-01-25 |
2006-03-08 |
Univ Erasmus Medical Ct |
Binding Molecules 2
|
|
KR101481843B1
(en)
*
|
2006-01-25 |
2015-01-12 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
Generation of heavy-chain only antibodies in transgenic animals
|
|
GB0618345D0
(en)
*
|
2006-09-18 |
2006-10-25 |
Univ Erasmus |
Binding molecules
|
|
US20100062004A1
(en)
|
2006-12-19 |
2010-03-11 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
WO2009138519A1
(en)
|
2008-05-16 |
2009-11-19 |
Ablynx Nv |
AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
|
|
GB0706628D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Univ Erasmus |
Germ-line manipulation 1
|
|
PT2336329E
(en)
|
2007-06-01 |
2012-12-24 |
Omt Inc |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
|
|
EP2215125A1
(en)
|
2007-11-27 |
2010-08-11 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
US9908943B2
(en)
|
2008-04-03 |
2018-03-06 |
Vib Vzw |
Single domain antibodies capable of modulating BACE activity
|
|
EP2281005B1
(en)
|
2008-04-03 |
2013-11-20 |
Vib Vzw |
Single domain antibodies capable of modulating bace1 activity
|
|
AU2009235467A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Single variable domains against the Notch pathways
|
|
WO2009143472A2
(en)
|
2008-05-23 |
2009-11-26 |
Aliva Biopharmaceuticals, Inc. |
Method of generating single vl domain antibodies in transgenic animals
|
|
SI2285408T1
(en)
|
2008-06-05 |
2019-02-28 |
Ablynx N.V. |
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
|
|
RU2011129459A
(en)
*
|
2008-12-18 |
2013-01-27 |
Эрасмус Юниверсити Медикал Сентр Роттердам |
TRANSGENIC ANIMALS (NOT HUMAN), EXPRESSING HUMANIZED ANTIBODIES, AND THEIR APPLICATION
|
|
AU2009329501B2
(en)
|
2008-12-19 |
2015-11-26 |
Ablynx N.V. |
Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
WO2011049449A1
(en)
|
2009-10-22 |
2011-04-28 |
University Of Twente |
Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
|
|
CN104131035A
(en)
|
2009-12-10 |
2014-11-05 |
瑞泽恩制药公司 |
Mice that make heavy chain antibodies
|
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
DK2505654T4
(en)
|
2010-02-08 |
2020-07-27 |
Regeneron Pharma |
Mouse with common light chain
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
EP2552962B1
(en)
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
GB201014715D0
(en)
|
2010-09-06 |
2010-10-20 |
Vib Vzw |
Nanobodies stabilizing functional conformational states of GPCRS
|
|
CA3250882A1
(en)
|
2010-08-02 |
2025-11-29 |
Regeneron Pharamaceuticals, Inc. |
Mice that Make Binding Proteins Comprising VL Domains
|
|
AU2011295018B2
(en)
|
2010-08-26 |
2015-04-09 |
Biotalys NV |
Compositions for seed treatment
|
|
ES2723775T3
(en)
|
2010-11-08 |
2019-09-02 |
Ablynx Nv |
Polypeptides that bind to CXCR2
|
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
|
US20150158948A9
(en)
|
2011-03-28 |
2015-06-11 |
Francis Descamps |
Bispecific anti-cxcr7 immunoglobulin single variable domains
|
|
UA117218C2
(en)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
|
|
CN107857810A
(en)
|
2011-06-21 |
2018-03-30 |
非营利性组织佛兰芒综合大学生物技术研究所 |
For GPCR:The binding structural domain of G-protein compound and the purposes from it
|
|
MY172718A
(en)
|
2011-08-05 |
2019-12-11 |
Regeneron Pharma |
Humanized universal light chain mice
|
|
MY172946A
(en)
|
2011-10-17 |
2019-12-16 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
|
KR102081657B1
(en)
|
2011-12-20 |
2020-02-26 |
리제너론 파마슈티칼스 인코포레이티드 |
Humanized light chain mice
|
|
EP2617732A1
(en)
|
2012-01-19 |
2013-07-24 |
Vib Vzw |
Tools and methods for expression of membrane proteins
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
JP6411333B2
(en)
|
2012-05-24 |
2018-10-24 |
ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ |
Anti-macrophage mannose receptor single variable domain for tumor-associated macrophage targeting and INVIVO imaging
|
|
HUE055617T2
(en)
|
2012-06-12 |
2021-12-28 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
US20150368339A1
(en)
|
2013-02-05 |
2015-12-24 |
Vib Vzw |
Muscarinic acetylcholine receptor binding agents and uses thereof
|
|
NO2951201T3
(en)
|
2013-02-08 |
2018-03-17 |
|
|
|
ES2678221T3
(en)
|
2013-02-20 |
2018-08-09 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
WO2014140376A1
(en)
|
2013-03-15 |
2014-09-18 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
CA2936728C
(en)
|
2014-01-30 |
2023-06-20 |
Vib Vzw |
Opioid receptor binding agents and uses thereof
|
|
BR112016021572A2
(en)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
METHODS FOR PREPARING A GENETICALLY MODIFIED NON-HUMAN ANIMAL AND FOR PRODUCING BINDING PROTEINS, HYBRIDOMA, NUCLEIC ACID, CELL, AND, BINDING PROTEIN
|
|
BR112016021679A2
(en)
|
2014-03-21 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
antigen binding protein, methods of producing an antigen binding protein and identifying one or more antigen binding proteins, hybridoma, nucleic acid, cell, and genetically modified non-human animal.
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
EP3932428A1
(en)
|
2015-05-21 |
2022-01-05 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
|
CN115850521A
(en)
|
2016-02-05 |
2023-03-28 |
奥里尼斯生物科学私人有限公司 |
Targeted therapeutics and uses thereof
|
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
|
EP3430055B1
(en)
|
2016-03-17 |
2020-10-28 |
Oslo Universitetssykehus HF |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
CN109563141A
(en)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
To the therapeutic targeting of cellular structures
|
|
IL263102B2
(en)
|
2016-05-20 |
2023-11-01 |
Harpoon Therapeutics Inc |
Single domain serum albumin binding protein
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
LT3461261T
(en)
|
2016-05-20 |
2025-08-25 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
KR20190087539A
(en)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
PSMA-targeted triple specific proteins and methods of use
|
|
US10849973B2
(en)
|
2016-11-23 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
JP2020505037A
(en)
|
2017-01-19 |
2020-02-20 |
オープン モノクローナル テクノロジー，インコーポレイテッド |
Human antibodies from transgenic rodents having multiple heavy chain immunoglobulin loci
|
|
MX2019009255A
(en)
|
2017-02-06 |
2019-11-05 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof.
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
KR102376863B1
(en)
|
2017-05-12 |
2022-03-21 |
하푼 테라퓨틱스, 인크. |
mesothelin binding protein
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
WO2018222587A1
(en)
|
2017-05-30 |
2018-12-06 |
The Regents Of The University Of California |
NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antibody immune effctor cell engagers and methods of use thereof
|
|
CN111630070B
(en)
|
2017-10-13 |
2024-07-30 |
哈普恩治疗公司 |
Trispecific proteins and methods of use
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B cell maturation antigen binding proteins
|
|
SG11202005273XA
(en)
|
2017-12-28 |
2020-07-29 |
Nanjing Legend Biotech Co Ltd |
Antibodies and variants thereof against pd-l1
|
|
KR20200104333A
(en)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Single-domain antibodies to TIGIT and variants thereof
|
|
TWI802633B
(en)
|
2018-01-15 |
2023-05-21 |
大陸商南京傳奇生物科技有限公司 |
Single-domain antibodies and variants thereof against pd-1
|
|
EP3743448A4
(en)
|
2018-01-26 |
2021-11-03 |
Orionis Biosciences, Inc. |
XCR1 LINKERS AND THEIR USES
|
|
US11896643B2
(en)
|
2018-02-05 |
2024-02-13 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
JP7346790B2
(en)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Single domain antibodies against LAG-3 and their uses
|
|
AU2019271138A1
(en)
|
2018-05-14 |
2021-01-07 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
CN117442717A
(en)
|
2018-06-01 |
2024-01-26 |
大有华夏生物医药集团有限公司 |
Compositions for treating diseases or conditions and uses thereof
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
CN112789293B
(en)
|
2018-09-10 |
2024-05-10 |
南京传奇生物科技有限公司 |
Single domain antibodies to CLL1 and constructs thereof
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
JP7538130B2
(en)
|
2019-01-23 |
2024-08-21 |
タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド |
Anti-PD-L1 diabodies and uses thereof
|
|
EP3969479B1
(en)
|
2019-05-14 |
2025-07-30 |
Harpoon Therapeutics, Inc. |
Epcam binding proteins and methods of use
|
|
CN110818795B
(en)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
anti-TIGIT antibodies and methods of use
|
|
WO2021168303A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
CN115066440A
(en)
|
2020-02-28 |
2022-09-16 |
上海复宏汉霖生物技术股份有限公司 |
anti-CD 137 constructs and uses thereof
|
|
EP4110826A4
(en)
|
2020-02-28 |
2024-08-14 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
|
IL298735A
(en)
|
2020-06-02 |
2023-02-01 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and their uses
|
|
CN116529260A
(en)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
anti-CD 93 constructs and uses thereof
|
|
JP2023530919A
(en)
|
2020-06-17 |
2023-07-20 |
ヤンセン バイオテツク，インコーポレーテツド |
Materials and methods for production of pluripotent stem cells
|
|
CA3190328A1
(en)
|
2020-07-29 |
2022-02-03 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
|
BR112023002488A2
(en)
|
2020-08-10 |
2023-05-02 |
Janssen Biotech Inc |
MATERIALS AND METHODS TO PRODUCE BIOMODIFIED LYMPHOCYTES AGAINST SPECIFIC VIRUSES
|
|
CN115279787B
(en)
|
2020-09-28 |
2024-06-07 |
安济盛生物医药有限公司 |
Anti-sclerostin constructs and uses thereof
|
|
WO2022156908A1
(en)
|
2021-01-25 |
2022-07-28 |
Vrije Universiteit Brussel |
Method for preparing a lyophilized composition
|
|
WO2022156907A1
(en)
|
2021-01-25 |
2022-07-28 |
Vrije Universiteit Brussel |
Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
|
|
WO2022157373A1
(en)
|
2021-01-25 |
2022-07-28 |
Vrije Universiteit Brussel |
Compositions and kits for in vivo imaging of cardiac sarcoidosis
|
|
US20240228613A9
(en)
|
2021-02-19 |
2024-07-11 |
Shaperon Inc. |
Single domain antibody against cd47 and use thereof
|
|
WO2022177393A1
(en)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Single domain antibody against pd-l1 and use thereof
|
|
US20240228670A9
(en)
|
2021-02-19 |
2024-07-11 |
Shaperon Inc. |
Bispecific single domain antibody to pd-l1 and cd47 and use thereof
|
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
|
EP4301472A1
(en)
|
2021-03-05 |
2024-01-10 |
Dynamicure Biotechnology LLC |
Anti-vista constructs and uses thereof
|
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
WO2023057508A1
(en)
|
2021-10-05 |
2023-04-13 |
Vrije Universiteit Brussel |
Fluorescently labeled immunoglobulin single variable domai ns
|
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
JP2025501522A
(en)
|
2021-12-17 |
2025-01-22 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
Anti-OX40 Antibodies and Methods of Use
|
|
AU2023240941A1
(en)
|
2022-03-25 |
2024-09-19 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-msln antibodies and methods of use
|
|
EP4558151A1
(en)
|
2022-07-22 |
2025-05-28 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
|
JP2025531788A
(en)
|
2022-09-07 |
2025-09-25 |
ダイナミキュア バイオテクノロジー エルエルシー |
Anti-VISTA constructs and uses thereof
|
|
EP4349374A1
(en)
|
2022-10-05 |
2024-04-10 |
Vrije Universiteit Brussel |
Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains
|
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
EP4512243A1
(en)
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
WO2025045250A1
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Anti-human factor d antibody constructs and uses thereof
|
|
WO2025088085A1
(en)
|
2023-10-26 |
2025-05-01 |
Abscint Nv |
Image guided biopsy of her2 positive lesions
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|